Fig. 4: Impact of NRF2 activation status on clinical outcomes.
From: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
a, Prevalence of NRF2 activation status for patients with available RNA-seq data (CB100 + CB200 sotorasib and docetaxel arms). b,c, Kaplan–Meier curves for PFS (b) or OS (c) based on NRF2 (high versus low) activation status for patients treated with sotorasib in the combined dataset. d,e, Kaplan–Meier curves of PFS (d) or OS (e) based on TTF1 (high versus low) mRNA expression and NRF2 (high versus low) activation status for patients treated with sotorasib in the combined dataset. NE, not estimable.
